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Abstract
Burkholderia cenocepacia is an opportunistic pathogen responsible for life-threatening
infections in cystic fibrosis patients. B. cenocepacia is extremely resistant towards antibiot-
ics and therapy is complicated by its ability to form biofilms. We investigated the efficacy of
an alternative antimicrobial strategy for B. cenocepacia lung infections using in vitro and in
vivo models. A screening of the NIH Clinical Collection 1&2 was performed against B. ceno-
cepacia biofilms formed in 96-well microtiter plates in the presence of tobramycin to identify
repurposing candidates with potentiator activity. The efficacy of selected hits was evaluated
in a three-dimensional (3D) organotypic human lung epithelial cell culture model. The in vivo
effect was evaluated in the invertebrate Galleria mellonella and in a murine B. cenocepacia
lung infection model. The screening resulted in 60 hits that potentiated the activity of tobra-
mycin against B. cenocepacia biofilms, including four imidazoles of which econazole and
miconazole were selected for further investigation. However, a potentiator effect was not
observed in the 3D organotypic human lung epithelial cell culture model. Combination treat-
ment was also not able to increase survival of infected G. mellonella. Also in mice, there was
no added value for the combination treatment. Although potentiators of tobramycin with
activity against biofilms of B. cenocepacia were identified in a repurposing screen, the in
vitro activity could not be confirmed nor in a more sophisticated in vitro model, neither in
vivo. This stresses the importance of validating hits resulting from in vitro studies in physio-
logically relevant model systems.
Introduction
Species belonging to the Burkholderia cepacia complex (BCC) are opportunistic pathogens
mainly known for causing chronic lung infections in cystic fibrosis (CF) patients and in
patients with chronic granulomatous disease [1,2]. Burkholderia cenocepacia belongs to the
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BCC and accounts for approximately 45% of BCC infections in CF patients in the United
States [1,2]. The complex interaction between B. cenocepacia and the CF lung is reflected by
the various clinical outcomes and disease severity, from transient colonization to necrotizing
pneumonia and sepsis resulting in early death [3]. In addition, respiratory infections caused by
B. cenocepacia are associated with lower survival following lung transplantation [4,5]. Antimi-
crobial therapy against these infections frequently fails due to B. cenocepacia’s resistance to
many antibiotics and the tolerance typically associated with a biofilm-specific lifestyle [6–8].
Compounds that improve the activity of antibiotics have been called helper compounds [9],
potentiators [10], adjuvants [11], or resistance breakers [12]. The aim of the present study was
to identify such compounds that reverse tolerance and/or resistance towards tobramycin by
increasing the susceptibility of B. cenocepacia biofilms. To this end, we screened a repurposing
library containing compounds that passed human safety assessments and for which the toxic-
ity and metabolic properties are already known [13]. Activity was evaluated in several in vitro
and in vivo assays.
Material and methods
Strains and culture conditions
B. cenocepacia LMG 16656 was maintained on tryptic soy agar plates (TSA, Lab M, Lancashire,
UK). Overnight suspensions were obtained by inoculating Mueller Hinton broth (MH, Lab
M) with several colonies and incubation with shaking for 18 h. A green fluorescent protein
(GFP) producing B. cenocepacia K56-2 mutant was maintained on Luria-Bertani agar (LB
agar, Lab M) supplemented with 800 μg/mL trimethoprim (Ludeco, Brussels, Belgium) [14].
Overnight suspensions were made in LB broth supplemented with 800 μg/mL trimethoprim
and inoculated for 23–24 h in a shaker (250 rpm). All cultures were kept aerobically at 37˚C.
Library compounds and antimicrobial agents
The NIH Clinical Collections 1&2 (NIHCC 1&2, Evotec, San Francisco, CA) contain 727
compounds dissolved in 100% dimethyl sulfoxide (DMSO) at a concentration of 10 mM.
Miconazole nitrate was obtained from Certa NV (Eigenbrakel, Belgium), meropenem from
Astrazeneca (Zoetermeer, The Netherlands), econazole nitrate, ketoconazole, ciprofloxacin,
and gentamicin sulfate from Sigma (Bornem, Belgium), oxiconazole nitrate from Santa Cruz
Biotechnology (Heidelberg, Germany), and tobramycin from TCI chemicals (Tokyo, Japan).
Azoles were dissolved in 100% DMSO (Sigma) and subsequently diluted in MilliQ water (MQ)
(Millipore, Billerica, MA) for MIC determination, in physiological saline (PS, 0.9% w/v NaCl)
for the checkerboard tests, for the tests with biofilms formed in 96-well microtiter plates
(MTPs) and for the G. mellonella assay, or in GTSF-2 medium for the 3D organotypic human
cell culture model [15]. Antibiotic stocks were made in MQ water or PS. All antibiotic solu-
tions were filter sterilized (0.22 μm, Whatman, Dassel, Germany) and immediately used.
Library screen and identification of hits
B. cenocepacia LMG 16656 biofilms were formed in round-bottomed 96-well MTPs as
described by Van den Driessche et al. [16]; after 24 h of biofilm formation they were treated
with one μl library compound (final concentration: 100 μM), 49 μL PS and 50 μL of a 1024 μg/
mL tobramycin solution (final concentration: 512 μg/mL). One μL of compound solution was
added to 99 μL PS for the experiments carried out in absence of tobramycin. An untreated
control, a control for tobramycin treatment alone and a blank were included on every plate.
After 24 h, biofilms were rinsed with 100 μL PS and the effect of the treatment was evaluated
Evaluation of combination therapy for Burkholderia cenocepacia
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using CellTiter-Blue staining (CTB, Promega, Leiden, The Netherlands). Fluorescence was
measured using a multilabel MTP-reader (Envision, Perkin Elmer LAS, Waltham, MA) as
described by Peeters et al. [17]. The blank corrected fluorescence signals generated by B. ceno-
cepacia biofilms treated with the combination of test compound and tobramycin were com-
pared to the fluorescence signals generated by biofilms that were treated with tobramycin
alone. Hits were defined as compounds that caused a decrease in fluorescence signal of 90%
in combination with tobramycin compared to the fluorescence signal generated by biofilms
treated with tobramycin alone. Hit compounds were also tested in absence of tobramycin and
the fluorescence generated was compared to that from the untreated control.
Determination of the in vitro activity of econazole and miconazole
against B. cenocepacia
To determine the MICs of miconazole and econazole, overnight B. cenocepacia LMG 16656
cell suspensions were adjusted to OD595 of 0.05 and diluted 1:50 in double concentrated MH.
Subsequently, 100 μL cell suspension was added to flat-bottomed 96-well MTP (SPL Life-
science, Korea) containing 100 μL of 1/2 serial diluted imidazole solutions (concentration
range 0–400 μM). OD590 was measured using a multilabel MTP reader (Envision) after 24 h.
MICs were determined in triplicate on different days.
Biofilms were formed as described above and treated with 50 μL 200 μM econazole or
miconazole (final concentration: 100 μM) and 50 μL 1024 μg/mL tobramycin (final concentra-
tion: 512 μg/mL). After 24 h, supernatants were removed and wells were rinsed. Cells were col-
lected from the wells by 2 cycles of shaking (5 min, 700 rpm, Titramax 1000) and sonicating (5
min, Branson 3570E-MT, Branson Ultrasonic Corporation, Banbury, CT). The content of 5
wells was pooled in tubes containing 9 mL PS and the number of CFU per biofilm (CFU/BF)
was determined by plating serial 10-fold dilutions on TSA plates. In addition, the potentiating
activity of lower concentrations of econazole and miconazole (1 and 10 μM) towards tobramy-
cin, as well as the combination of 100 μM econazole with meropenem (320 and 3200 μg/mL),
ciprofloxacin (250 μg/mL) and gentamicin (512 and 2560 μg/mL) was evaluated in the same
model system. Experiments were performed in triplicate on different days.
For checkerboard assays biofilms were treated with tobramycin (64–8192 μg/mL) and eco-
nazole (25–200 μM) or miconazole (25–200 μM). Potential synergistic activity of these treat-
ments was assessed by calculation of the fractional inhibitory concentration index (FICI)
based on metabolic activity determination using CTB. In detail, FICI was calculated as FICI =
(CTOB+IMI/CTOB)+(CIMI+TOB/CIMI), where CTOB+IMI is the concentration of tobramycin in the
presence of the imidazole at which the fluorescence generated is equal to the fluorescence of
the blank control, CTOB is the concentration of tobramycin that causes a fluorescence equal
to the fluorescence of the blank control, CIMI+TOB is the concentration of the imidazole that
causes in the presence of tobramycin a fluorescence signal equal to that of the blank control
and CIMI is the concentration of the imidazole that causes a fluorescence signal equal to
the fluorescence signal of the blank control. Interactions were scored as synergistic when
FICI 0.5 [18].
Evaluation of the effect of econazole or miconazole and tobramycin in a
3D organotypic human cell culture model
A 3D human lung epithelial cell culture model was generated by growing A549 cells (ATCC
CCL-185) on porous microcarrier beads in a low fluid shear bioreactor, as previously de-
scribed [19,20]. A549 cells were maintained in GTSF-2 medium supplemented with 2.5 mg/L
insulin transferrin selenite (ITS, Sigma-Aldrich), 1.5 g/L sodium bicarbonate, and 10% heat-
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inactivated fetal bovine serum (FBS, Life Technologies). All cultures were grown at 37˚C
under 5% CO2 conditions. Infection studies were performed using 3D cultures grown for 11 to
14 days, and at the time of infection cell culture medium without FBS and supplemented with
0.2% rhamnose was used. 3D cell cultures containing 2.5 x 105 cells in 250 μL per well were
transferred to 48-well plates (SPL Life Sciences). An overnight culture of a GFP-producing B.
cenocepacia K56-2 mutant [14] was resuspended in cell culture medium and added to the 3D
cells at a multiplicity of infection of ~15:1. Treatments (156 μg/mL tobramycin and/or 10 μM
econazole or miconazole) were added to the cell culture medium at the start of the infection.
Plates were incubated at 37˚C under 5% CO2 conditions for 1 h, rinsed with Hanks’ Balanced
Salt Solution (HBSS, Life Technologies) and subsequently fresh cell culture medium contain-
ing the treatment reagents was supplied. After 16 h additional incubation, the number of B.
cenocepacia that associated with the 3D cells was determined. To this end, the content of each
well was transferred to new wells to avoid inclusion of bacteria attached to the plastic surface.
Cultures were rinsed twice with HBSS followed by the addition of 0.1% Triton X-100, vigorous
mixing and plating. The experiments were performed in the absence and presence of 3D
cells, under otherwise identical conditions, to assess the effect of tobramycin and/or imidazoles
on the inhibition of bacterial association with an abiotic or biotic surface, respectively. Con-
trols with no antimicrobials and uninfected 3D cell cultures were included in every assay.
Assessment of the overall 3D cell culture model integrity and visualization of GFP-producing
bacteria was performed using an EVOS FL Auto Imaging System (Life Technologies) at a mag-
nification of 300x. In addition, the 3D lung epithelial cell viability was evaluated based on a lac-
tate dehydrogenase (LDH) assay. The LDH activity assay kit (Sigma) was used to measure the
release of cytosolic LDH by 3D lung epithelial cells following exposure to B. cenocepacia K56-
2. Medium from 3D aggregates infected with B. cenocepacia for 17 h was centrifuged for 15
minutes at 3700 rpm, where after the supernatants was used for LDH quantification following
the manufacturer’s instructions. A standard curve using NADH was included. As a positive
control, 2.5 x 105 3D lung epithelial cells were lysed with 0.1% Triton-X100 in 250 μL (the
same volume as for the test conditions). The experiments were performed in triplicate on dif-
ferent days. The data are presented as a percentage of LDH release from the positive control.
Evaluation of the potentiating effect in a Galleria mellonella infection
assay
In vivo activity of tobramycin and econazole or miconazole was evaluated in the G. mellonella
infection assay, as described by Brackman et al [21]. G. mellonella larvae (Hengelsport de Poor-
ter, Ghent, Belgium) were kept at 4˚C in the dark on wooden flakes prior to use and divided in
groups with similar weight distribution (300–450 mg, 450–550 mg or 550–650 mg). Equal
amounts of larvae were taken from each group to compose new groups containing at least 12
larvae for the infected groups and 6 for the uninfected groups. Overnight cultures of B. cenoce-
pacia LMG 16656 were centrifuged, resuspended in PS and adjusted to 107 CFU/mL. Larvae
were injected with 10 μL cell suspension in the last left proleg and 10 μL of the treatment solu-
tion (512 μg/mL tobramycin, 50 μM econazole, 50 μM miconazole, or combinations) in the
last right proleg using a syringe (BD ultrafine insulin syringes, Becton Dickinson, Erembode-
gem, Belgium). Larvae were incubated at 37˚C and survival was scored after 24, 48 and 72 h.
Larvae were considered dead when no movement was observed in response to touch. To deter-
mine whether the treatment caused a reduction in the number of CFU/larvae 24 h post infec-
tion (p.i.), larvae were homogenized (Polytron, Kinematica, Eschbach, Germany), serially
diluted and plated on Burkholderia cepacia selective agar (Thermo Scientific, Erembodegem,
Belgium).
Evaluation of combination therapy for Burkholderia cenocepacia
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Development of a formulation for inhalation containing tobramycin and
miconazole
In contrast to tobramycin which is highly soluble in water, miconazole is very slightly soluble
in water [22]. Therefore, it was decided to formulate the combination tobramycin-micona-
zole as a suspension for nebulization. In order to decrease the particle size of the suspended
miconazole particles (i.e., down to desired particle size for deposit in the lungs), the wet bead
milling technique was applied. The formulation was prepared by weighing 330 mg tobramy-
cin and 15.4 mg or 61.6 mg miconazole into a 20 mL vial, followed by the addition of 1 mL
Tween 80 solution (1 mg/mL) (Fagron, Waregem, Belgium), 4 mL PS, and 10 g zirconium
oxide beads (diameter 0.5 mm, Netzsch Feinmahltechnik, Selb, Germany). Subsequently, the
vials were placed on a roller-mill (Peira, Beerse, Belgium) and grinding was performed at 150
rpm for 72 h. After milling, the microsuspension was separated from the grinding pearls by
pipetting. The particle size distribution of miconazole was measured in triplicate by laser dif-
fraction (Mastersizer S long bench, Malvern Instruments, Worcestershire, UK). The wet dis-
persion technique was applied using the 300RF lens (Malvern Instruments, Worcestershire,
UK). The powders were dispersed in a solution of 0.2% Tween 80 in Miglyol 812 and subse-
quently vortexed and sonicated in order to eliminate agglomerates. In addition, biofilms
formed in 96-well MTPs were treated with the formulation in a dilution of 1 in 129 (corre-
sponding to 512 μg/mL tobramycin and 200 μM miconazole) to confirm the antibacterial
activity. Experiments were performed six times independently and the effect was quantified
by plate counts.
Mouse lung infection model
Animals were treated in accordance to the guidelines provided by the University of Antwerp
and the European Directive for Laboratory Animal Care (Directive 2010/63/EU of the Euro-
pean Parliament). The laboratory Animal Ethics Committee of the University of Antwerp
authorized and approved all animal experimentation in this study (file 2014–81). Female
inbred BALB/c ByJRj mice of 8–9 weeks old (Janvier Labs, Le Genest-Saint-Isle, France) were
kept under standard pathogen-free conditions with a constant temperature of 20–25˚C, an
average humidity of 50–60%, a 12 h dark-light cycle and food and drinking water ad libitum.
Mice were rendered transiently leukopenic with cyclophosphamide (Endoxan, Baxter) at 150
mg/kg body weight (bw) given intraperitoneally 4 days prior to infection and 50 mg/kg bw
administered both 2 days prior to infection and on the day of infection. To prepare the inocu-
lum for intratracheal infection, a bacterial cryostock was thawed, diluted in LB broth (105
CFU/mL) and incubated for 24 h in a shaken incubator (25 rpm) at 37˚C in a 14 mL vent cap
sterile tube. Cells were harvested by centrifugation after 24 h and diluted in PBS to 2 x 107
CFU/mL. Before intratracheal challenge with B. cenocepacia, mice were anesthetized with iso-
flurane (Halocarbon, Norcross, GA) and all efforts were made to minimize suffering. Anesthe-
tized mice were inoculated intratracheally with B. cenocepacia (106 CFU/mouse) in 50 μL of
PBS according to Dupage et al. [23],. Thereafter, infected mice were treated intranasally with
40 μl of the formulations described above, i.e. vehicle (0.02% Tween 80 dissolved in PS), tobra-
mycin (66 mg/mL, corresponding to 120 mg/kg bw), miconazole (3.08 mg or 12.32 mg/mL
corresponding to 5.6 and 22.4 mg/kg bw miconazole, respectively), and the combination, at
1 h, 24 h and 48 h p.i. according to Southam et al. [24]. Mice were observed daily for functional
behavior (i.e. fur quality, posture, state of activity and bw) and pneumonia symptoms (i.e.
respiratory frequency). B. cenocepacia infected mice were sacrificed at day 3 p.i. by cervical dis-
location. Lung, spleen and liver were excised, weighed and homogenized in 5 mL PBS and
were used for the enumeration of CFU on LB agar or Burkholderia cepacia selective agar.
Evaluation of combination therapy for Burkholderia cenocepacia
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Statistics
Data are expressed as the mean ± standard error of the mean (SEM). SPSS version 23 software
was used and data were analyzed using the Kruskal-Wallis test. P-values < 0.05 were consid-
ered statistically significant.
Results
Library screen against B. cenocepacia biofilms in combination with
tobramycin
Screening the NIHCC 1&2 against B. cenocepacia biofilms in the presence of tobramycin
allowed us to identify 60 hits (8.2%). In the presence of tobramycin these hit compounds
caused a decrease of 90% in fluorescence signal after CTB staining compared to treatment
with tobramycin alone (S1 Table). Hits were classified in four groups according to their thera-
peutic indication: anti-infective agents (n = 11), antipsychotics and antidepressants (n = 23),
antineoplastic and/or hormonal drugs (n = 6), and a miscellaneous group (n = 20) (S2 Table).
Subsequently, B. cenocepacia biofilms were treated with the hit compounds alone; 19 com-
pounds did not cause a significant decrease in fluorescence, indicating they are true potentia-
tors. In contrast, 41 compounds caused a significant reduction in fluorescence compared to
the untreated control suggesting their potentiating activity is at least partially due to an intrin-
sic activity against B. cenocepacia biofilms (S2 Table).
Antifungal imidazoles are potentiators in vitro
Four antifungal imidazoles, i.e. econazole, miconazole, oxiconazole, and ketoconazole were
identified as hits in the screening. Treatment of biofilms with econazole alone reduced the
fluorescence significantly compared to the untreated control. Miconazole, oxiconazole, and
ketoconazole did not cause a significant reduction in fluorescence compared to untreated con-
trol (S2 Table).
Subsequently, B. cenocepacia biofilms were treated with 100 μM econazole or miconazole
in combination with 512 μg/mL tobramycin and the antimicrobial effect was quantified
by plate counts. Treatment with econazole or miconazole alone did not cause a reduction
in the number of CFU/BF. However, in combination with tobramycin, a significant reduc-
tion in the number of CFU/BF was observed, compared to treatment with tobramycin alone
(Fig 1). Lower concentrations of econazole and miconazole were tested for potentiating
activity towards tobramycin; there was no potentiator activity for 1 μM, while 10 μM econa-
zole or miconazole were equally effective as 100 μM (Fig 1). The potentiator activity of
econazole was subsequently investigated in combination with other antibiotics; 100 μM
econazole caused a statistically significant reduction in CFU/BF in combination with
2560 μg/mL gentamicin, but not with 512 μg/mL gentamicin. Econazole did not potentiate
the activity of meropenem or ciprofloxacin (Fig 1). In addition, we confirmed that treat-
ment with econazole or the combination tobramycin–econazole did not lead to induced
dispersion (S1 Fig).
The MIC for econazole and miconazole against B. cenocepacia exceeded 200 μM. Subse-
quently, checkerboard assays were performed against biofilms of B. cenocepacia and showed
that in the presence of the imidazoles, the concentration of tobramycin necessary to com-
pletely eradicate biofilms decreased substantially. As the imidazoles alone did not eradicate
biofilms in the concentrations tested, and as higher concentrations could not be tested due to
solubility issues, exact FICIs could not be calculated.
Evaluation of combination therapy for Burkholderia cenocepacia
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Evaluation of the activity of the combination treatment in a 3D
organotypic cell culture model
B. cenocepacia K56-2 infected 3D lung epithelial cells without significantly affecting the 3D
model integrity (Fig 2) and host cell viability (S2 Fig) untill 17 h post infection. Specifically,
based on the LDH release assay less than 10% cell death of infected cultures was observed,
which was similar to that observed in the non-infected controls (S2 Fig).
Fig 1. Treatment of mature biofilms formed in 96-well MTPs. Number of CFU per biofilm after treating
mature biofilms of B. cenocepacia LMG 16656 for 24 h with 100 μL PS (untreated control, CTRL), 1, 10,
100 μM econazole (ECO) or 1, 10, 100 μM miconazole (MICO), in combination with 512 μg/mL tobramycin
(TOB), 512 and 2560 μg/mL gentamicin (GEN), 320 and 3200 μg/mL meropenem (MEM), or 250 μg/mL
ciprofloxacin (CIP). Asterisks indicate a significantly different number in log CFU/BF compared to treatment
with the respective antibiotic alone (P value < 0.05). (Data shown are average; n 3; error bars indicate
SEM).
doi:10.1371/journal.pone.0172723.g001
Fig 2. Infection of 3D lung epithelial cells. Left image showing an uninfected control where the microcarrier
bead scaffolds are covered with A549 human lung epithelial cells, right image shows the 3D lung epithelial
cells 17 h p.i., green dots (white arrows) indicate intracellular growth of B. cenocepacia K56-2, while the large
green structure (blue arrow) suggests that biofilm-like structures are formed. Magnification is 300x. Scale bar
is 400 μm.
doi:10.1371/journal.pone.0172723.g002
Evaluation of combination therapy for Burkholderia cenocepacia
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B. cenocepacia associated with the 3D lung epithelial cells both as dense clusters associated
with single host cells and as structures that were spread out over multiple epithelial cells
(Fig 2).
3D lung epithelial cells were exposed to 10, 50 and 100 μM of the imidazoles in the absence
of B. cenocepacia for 17 h (S3 Fig). The epithelial cells completely detached from their micro-
carrier bead scaffolds when exposed to 50 or 100 μM econazole or miconazole; this was not
observed when cells were exposed to 10 μM of the imidazoles (S3 Fig) and the latter concentra-
tion was chosen for further experiments. High concentrations of tobramycin (1000 μg/mL)
did not affect the 3D lung model integrity (S3 Fig). Adding 10 μM econazole or miconazole
led to an additional reduction in B. cenocepacia biofilm formation in MTP in combination
with 156 μg/mL tobramycin (test concentration of tobramycin determined in preliminary
experiments, S4 Fig), and this concentration was used to assess the number of viable and cul-
turable bacteria associated with 3D cells. When the combination treatment was tested in this
model, no potentiating effect of miconazole and econazole was observed, while the activity of
tobramycin was similar as in the MTP (Fig 3).
G. mellonella survival assay
G. mellonella larvae were injected with B. cenocepacia and treated with 10 μL vehicle (PS),
512 μg/mL tobramycin, 50 μM miconazole, 50 μM econazole, tobramycin combined with
miconazole, or tobramycin combined with econazole. No significant decrease in survival after
24, 48, and 72 h was observed in the non-infected groups that received the different treatments
which indicated that the treatment is not toxic at the concentrations applied. However, more
than 50% of the larvae had died in the infected groups 48 h p.i., regardless of the treatment
Fig 3. Effect of treatment in the 3D model. Effect of treatment with 10 μM econazole (ECO), 10 μM
miconazole (MICO), 156 μg/mL tobramycin (TOB) or the combination on inhibition of biofilm formation of B.
cenocepacia K56-2 with a plastic surface (left, number of biofilm cells per well) or the effect on the treatment
on the number of bacterial cells associated with human 3D lung epithelial cells (right, number of host
associated cells per well). Asterisks indicate a significantly different number in CFU/well compared to
treatment with tobramycin (P value < 0.05). (Data shown are average; n 3; error bars indicate SEM).
doi:10.1371/journal.pone.0172723.g003
Evaluation of combination therapy for Burkholderia cenocepacia
PLOS ONE | DOI:10.1371/journal.pone.0172723 March 1, 2017 8 / 16
which indicated that the treatment cannot protect the larvae against B. cenocepacia infection
(Fig 4).
These observations were confirmed by the fact that no differences in CFU/larvae were
observed among the different groups 24 h p.i. (S5 Fig).
Evaluation of the combination tobramycin and miconazole in a mouse
lung infection model
The combination of tobramycin and miconazole was evaluated in a B. cenocepacia mouse lung
infection model. To this purpose, a formulation for inhalation was developed in which the par-
ticle size was lower than 5 μm (i.e., d10 = 0.23 μm, d50 = 0.41 μm and d90 = 3.68 μm), which is
suitable for drug deposition in the lungs [25]. The formulation was found to be stable over 5
days (i.e. no shift in d50-value) which covered the duration of the in vivo study. The tobramycin
concentration (120 mg/kg bw) used for the treatment of B. cenocepacia infected mice is about
129 times the concentration used in the MTP assay. The concentration of miconazole in the
formulation was based on the ratio tobramycin/miconazole in the MTP experiments and the
activity of the diluted formulation was confirmed against biofilms formed in 96-well MTPs (S6
Fig). Treatment of infected mice with tobramycin resulted in prevention of dissemination to
liver and spleen, and a reduction in lung burden of approx. 1 log (Fig 5).
Mice treated with 22.4 mg/kg bw miconazole suffered from side effects and were character-
ized by a hunchback posture, weak breathing and an overall bad fur condition. Also dissemi-
nation of bacteria to liver and spleen was observed in every miconazole treated mouse,
whereas only approx. half of the vehicle-treated mice (5/11) had dissemination of bacteria to
liver and spleen (Fig 5). Therefore, a lower dose of miconazole (5.6 mg/kg bw) was chosen for
the evaluation of the combination therapy in mice. As shown in Fig 5, no significant difference
in lung burden could be observed between mice treated with tobramycin and tobramycin
combined with miconazole. Also mice treated with this lower dose of miconazole alone suf-
fered from the same toxic effects as 22.4 mg/kg bw miconazole.
Fig 4. G. mellonella survival assay. Percentage survival of G. mellonella in uninfected control groups (NI)
and infected groups (I) 24, 48, and 72 h after administration of the different treatments (tobramycin (TOB,
512 μg/ml), econazole (ECO, 50 μM), miconazole (MICO, 50 μM) or the combinations) and/or infection. (Data
shown are average, n = 6, error bars indicate SEM).
doi:10.1371/journal.pone.0172723.g004
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Discussion
Library screening identifies antifungal imidazoles as antibacterial
potentiators
Screening two repurposing libraries against B. cenocepacia biofilms in the presence of tobra-
mycin resulted in the identification of 60 hit compounds. Four antifungal imidazoles, i.e. eco-
nazole, miconazole, oxiconazole, and ketoconazole were among the hits identified. Other
azoles present in the library were less or not active, e.g. the triazoles fluconazole, itraconazole,
or voriconazole. This is in accordance with results from a structure-activity relationship study
on several oxiconazole derivatives in which compounds with an imidazole moiety were shown
to be more potent antibacterials against Klebsiella pneumoniae, Escherichia coli and Staphylo-
coccus aureus compared to triazoles [26]. The MIC of econazole and miconazole against B. cen-
ocepacia exceeded 200 μM, indicating that they potentiate tobramycin at concentrations that
do not inhibit growth of planktonic cells when administered alone. This is in accordance with
a study in which no growth inhibitory activity was observed for miconazole against planktonic
cells of Pseudomonas aeruginosa and E. coli, while the combination of miconazole with poly-
myxin B resulted in a strong synergistic interaction [27].
The activity of imidazoles towards Gram-positive bacteria has been described before [28–
31]. Sud and Feingold investigated the bactericidal effect of miconazole and concluded that
interference with the membrane of Gram-positive bacteria results in leakage of K+ [28]. In
addition, imidazoles bind S. aureus flavohemoglobin, a protein with NO dioxygenase activity,
causing nitrosative and oxidative stress [32]. Miconazole also binds flavohemoglobin of E. coli,
and in vitro data showed that the combination of a NO-donor, miconazole and polymyxin B
nonapeptide were effective to treat four ESBL-producing E. coli isolates [33].
Activity of the combination in relevant model systems
Activity of tobramycin in combination with econazole or miconazole was tested in an in vitro
3D organotypic human cell culture model. 3D organotypic cell culture models are valuable
research tools that mimic key aspects of the parental tissue and reduce the gap between in vitro
cell culture models and physiological tissue [34,35]. A 3D A549 lung epithelial cell culture
model has previously been developed and validated, and was used to study the colonization of
P. aeruginosa and Francisella tularensis. These studies demonstrated that the 3D lung epithelial
cells generated more in vivo-like phenotypes compared to conventional monolayers [20,36]. B.
cenocepacia has been shown to both cause intracellular infections and form biofilms in the
lungs of CF patients [8,37,38]. However, the biofilm formation capacity of Burkholderia species
in CF lungs is still under debate [39]. Infection of the 3D lung epithelial model with B. cenoce-
pacia K56-2 reflected aspects of the in vivo infection profile, as phenotypic characteristics that
were indicative of both intracellular growth and biofilm formation were observed. In the
absence of 3D cells, tobramycin showed an increased inhibition on biofilm formation in MTP
in the presence of econazole or miconazole (Fig 3, left part), so the imidazoles tested both
potentiate the biofilm-inhibiting and biofilm-eradicating activity of tobramycin. However, no
Fig 5. Effect of the combination therapy in a mouse lung infection model. Colony counts in lung (a),
spleen (b), and liver (c) in mice treated with: (i) vehicle, (ii) 22.4 mg/kg bw miconazole (MICO), (iii) 5.6 mg/kg
bw miconazole, (iv) 120 mg/kg bw tobramycin (TOB) and (v) 120 mg/kg bw tobramycin combined with 5.6 mg/
kg bw miconazole (TOB + MICO). Error bars indicate SEM. Three independent repeats of mice treated with
vehicle (n 3), two independent repeats of mice treated with MICO 22.4 mg/kg (n 3), one independent
repeat of mice treated with MICO 5.6 mg/kg (n = 2), one independent repeat of mice treated with TOB 120 mg/
kg (n = 6) and one independent repeat of mice treated with TOB + MICO (n = 6).
doi:10.1371/journal.pone.0172723.g005
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potentiating effect could be observed when 3D long epithelial cells were present (Fig 3, right
part).
The effect of the combination treatment was also evaluated in G. mellonella, which is a suit-
able model to test BCC virulence [40]. G. mellonella was used before to estimate the activity of
treatments towards B. cenocepacia infections, including novel agents with potentiator activity
[21]. Neither treatment with tobramycin, miconazole, econazole, nor the combination could
protect the larvae against B. cenocepacia infection (Fig 4).
Finally, the combination of tobramycin and miconazole was evaluated in a B. cenocepacia
mouse lung infection model. As 22.4 mg/kg bw miconazole demonstrated side effects, a lower
dose of miconazole (5.6 mg/kg bw) was chosen for the evaluation of the combination therapy
in mice. This dose is far below LD50 values for mice reported in literature, which range from
80 mg/kg for intravenous administration, to 220 mg/kg for intraperitoneal administration,
and even up to 519 mg/kg upon oral administration [41]. However, also this lower dose
appeared to be toxic for the mice used in the present study and no significant difference in
lung burden could be observed between mice treated with tobramycin, and those treated with
tobramycin and miconazole.
Different activity in a conventional in vitro biofilm model system and other
model systems of host-pathogen interactions
Based on in vitro data the promising combination of tobramycin with econazole or miconazole
was evaluated in other model systems which all indicated that the combination did not im-
prove the outcome upon infection with B. cenocepacia infection. Discrepancies in antimicro-
bial activity between in vitro and in vivo situations are often observed [42]. This may be
because basic in vitro models for susceptibility testing lack host factors (e.g. cellular and
humoral immunity of the host, the pathogen’s level of expression of virulence determinants
and protein binding). Also, pharmacokinetic parameters as penetration into the site of infec-
tion are not taken into account. In the present study azoles lost their potentiating activity
when they were investigated in models including host factors and it is thus likely that these
host factors play a role in their inactivation. Protein binding of miconazole (reported to be
90%) might contribute to a substantial decrease in biologically active free fraction and loss
of activity in the three models [43]. Also, a differential transcriptomic and phenotypic profile
in the presence of host cells might result in a reduced susceptibility to the combination
treatment.
The screening described in the present study was performed in one of the most frequently
used models for the evaluation of novel biofilm inhibitory/eradication compounds, i.e. the
static MTP biofilm model system [44]. Although this system has multiple advantages, it lacks
many of the micro-environmental factors that are encountered during the natural course of
infection of B. cenocepacia, including host components. Therefore, more advanced in vitro and
in vivo model systems for screening of antibacterials should be considered that are more reflec-
tive of the host environment and thus may better predict the efficacy of the combination ther-
apy. Of course, the suitability and predictive power of these model systems will need to be
validated prior to use.
Supporting information
S1 Table. Results of the NIHCC 1&2 libraries screening for potentiators. The NIH Clinical
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the left column represent the mean residual metabolic activity of the compound in the pres-
ence of tobramycin compared to treatment with tobramycin alone, and the standard deviation.
The values in the right column represent the mean residual metabolic activity of the com-
pound compared to untreated control, and the standard deviation.
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S2 Table. Overview of the hits identified after screening the NIH Clinical Collection 1&2
against biofilms of B. cenocepacia. Hits are classified according to their therapeutic indica-
tion. Compounds were tested at a concentration of 100 μM in the presence or absence of
tobramycin (512 μg/ml). The values shown in the left column represent the mean residual met-
abolic activity of the compound in the presence of tobramycin compared to treatment with
tobramycin alone, and the standard deviation. The values in the right column represent the
mean residual metabolic activity of the compound compared to untreated control, and the
standard deviation. X means that the compounds did not cause a significant difference in fluo-
rescence signal compared to the signal of untreated biofilms. SNRI: serotonin-norepinephrine
reuptake inhibitor, SSRI: serotonin reuptake inhibitor, TCA: tricyclic antidepressant.
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S1 Fig. Number of CFU recovered from the biofilm, the supernatant, and the washing
fluid, after treatment with econazole (100 μM), tobramycin (512 μg/ml), or the combina-
tion of both. Data shown are log CFU/biofilm or log CFU/ml (for supernatant or washing
fluid). The data shown are the average of four biological replicates (error bars represent stan-
dard error).
(TIF)
S2 Fig. Lactate dehydrogenase (LDH) release assay of 3D A549 lung epithelial cells that
were non-infected and infected with B. cenocepaciaK56-2 for 17h. LDH release is presented
as a percentage of a positive control (3D lung epithelial cells lysed with Triton-X100). Data
shown are average, error bars indicate SD.
(TIFF)
S3 Fig. Evaluation of the treatments’ toxicity in the 3D cell culture model. Exposure of 3D
A549 lung epithelial cells for 17 h to 10, 50, 100 μM econazole (B, E, G); 10, 50, 100 μM micon-
azole (C, F, H) or 1000 μg/mL tobramycin (D). A control condition where no antimicrobial
agents were added is also included (A). High concentrations of the imidazoles resulted in
detachment of host cells from microcarrier beads. Magnification is 300x. Scale bar is 400 μm.
(TIFF)
S4 Fig. Number of CFU recovered from B. cenocepacia biofilm after treatment with vary-
ing concentrations of tobramycin (alone or combined). Biofilms of B. cenocepacia K56-2
were grown in 48-well MTP in the presence of tobramycin (T, in μg/ml) with 10μM econazole
(E) or miconazole (M) to determine the optimal concentration for the tests in 3D human lung
epithelial cells. (Data shown are average, n3, error bars indicate SD)
(TIF)
S5 Fig. Determination of the bacterial load in G. mellonella. G. mellonella was infected with
B. cenocepacia LMG 16656 and treated with tobramycin (TOB), econazole (ECO), or the com-
bination. CFU/larvae was determined 24 h p.i. and treatment. Larvae were homogenized and
plated on selective Burkholderia medium. (Data shown are average, n3, error bars indicate
SEM).
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S6 Fig. Evaluation of the in vitro effect of our formulation for inhalation. In order to evalu-
ate the antimicrobial activity of a formulation for inhalation prior to use in the mouse lung
infection model, biofilms of B. cenocepacia LMG 16656 were formed in 96-well MTPs and sub-
sequently treated with the diluted (129x) formulation. This diluted formulation corresponds to
vehicle (tween 80 dissolved in PS), 512 μg/mL tobramycin (TOB), 200 μM miconazole (MICO)
or the combination of tobramycin and miconazole. The asterisk indicates a significantly differ-
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(Data shown are average, n3, error bars indicate SEM).
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